Cardiovascular Disease
Top in cardiology: FDA OKs gout drug to reduce CV events; studies support SGLT2 inhibitors
A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.
‘Simply stunning’: Bempedoic acid may cut CVD risk for primary prevention patients by 30%
SAN DIEGO — In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse CV events by 30% compared with placebo, researchers reported.
Research shows ‘substantial’ cardiovascular risk among patients with head and neck cancer
Individuals with newly diagnosed head and neck squamous cell carcinoma are at high risk for adverse cardiovascular events, results of a retrospective study of U.S. veterans showed.
Higher time in range reduces risks for CV events, severe hypoglycemia in type 2 diabetes
People with type 2 diabetes who spend more time in glycemic range have lower risks for major adverse cardiovascular events, severe hypoglycemia and microvascular events, according to a post hoc analysis of the DEVOTE trial.
PCOS associated with increased mortality risk
CHICAGO — Women with polycystic ovary syndrome may have an increased mortality risk, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS, according to a study presented at ENDO 2023.
TRAVERSE: Men using testosterone replacement do not have increased risk for CV events
CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial.
Bariatric surgery reduces need for lipid-lowering, diabetes medications long term
Adults with obesity who undergo bariatric surgery are less likely to use lipid-lowering, cardiovascular and diabetes medications after surgery compared with those who do not have surgery, according to study findings.
Escape Room Experience: LDL-Lowering Therapy and Beyond - Applying Advances to Patient Care
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Antiphospholipid antibodies indicate higher risk for future cardiovascular events
Anticardiolipin IgA and a2GPI IgA positivity, together at a single time point, indicate an increased risk for future atherosclerotic cardiovascular disease events, according to data published in JAMA Network Open.
Team-based intervention reduces risk for hypertension complications
A team-based, multicomponent program was linked to risk reductions for several CVD and health outcomes in patients with hypertension when compared with usual care, according to researchers.